2024 Revenues ($USD) : $2.98B
BioNTech generated €2.75B ($2.98B) in revenue for 2024, down from €3.82B in 2023 as COVID-19 vaccine demand declined. The company has provided 2025 revenue guidance of €1.7B ($1.85B) but maintains a strong financial position with €17.4B in cash and securities. BioNTech is actively transitioning its focus to its oncology pipeline, with promising developments in personalized cancer vaccines and strategic acquisitions such as Biotheus. Multiple data readouts expected in 2025 could potentially provide catalysts for future growth.